This study is looking at a new treatment called TEMMA (Targeted Embolization for Migraine Management) for people with severe migraine headaches that haven't improved with other medicines. TEMMA is a procedure that targets specific blood vessels in the brain that may contribute to migraine. Researchers want to see if this treatment is safe, possible to do, and if its benefits last over time. You might be able to join if you are 18-60 years old, have migraine at least 8 days a month, and have tried at least two other migraine prevention medicines without success. The main goal is to see how many fewer headache days you have 12 months after the treatment.

Study design

This is a single-site study where all participants receive the TEMMA treatment. It is an open-label study, meaning both you and your doctors will know you are receiving the treatment. About 25 people are expected to participate.

What's involved

You would undergo a baseline assessment period, including keeping a headache diary. After the TEMMA procedure, you would continue to track your headaches and complete surveys for 12 months.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 12 months after the embolization procedure to assess changes in headache days and other migraine-related outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.